Accessibility Menu
Novo Nordisk A/s logo

Novo Nordisk A/s

(OTC) NONOF

Current Price$50.74
Market Cap$224.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+220%
5 Year+27%
1 Year-19%
1 Month+15%
Novo Nordisk A/s last closing stock price
MetricPriceDate
Last closeUSD 50.742026-07-17
Novo Nordisk A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.27%USD 48.202026-07-10
1 month+15.3%USD 44.012026-06-17
3 month+32.08%USD 38.422026-04-17
Year to date+2.96%USD 49.292025-12-31
1 year-18.76%USD 62.462025-07-17
3 year-31.09%USD 73.642023-07-18
5 year+27.28%USD 39.872021-07-16
Since inception+219.69%USD 15.872003-07-31

Novo Nordisk A/s Financials at a Glance

Market Cap

$224.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 327.62B

Net Income (TTM)

DKK 121.90B

EPS (TTM)

$4.26

P/E Ratio

11.90

Dividend

$1.80

Beta (Volatility)

0.50 (Low)

Price

$50.74

Volume

207,168

Open

$48.40

Previous Close

$50.74

Daily Range

$48.00 - $52.17

52-Week Range

$34.00 - $72.61

Estimated Earnings Date

Aug 5, 2026

NONOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novo Nordisk A/s

Novo Nordisk A/S is a leading global pharmaceutical company focused on the discovery, development, production, and distribution of a diverse range of medicinal products. Established in 1923 and headquartered in Bagsvaerd, Denmark, the company operates primarily in two segments: Diabetes and Obesity Care, and Biopharmaceuticals.

Products and Services
  • Insulin preparations and GLP-1 receptor agonists for diabetes management
  • Oral antidiabetic medications and weight management therapies
  • Specialized treatments for hemophilia and hormone replacement therapy
Growth Outlook
  • Strong demand for diabetes and obesity care products drives revenue growth
  • Strategic collaborations enhance research capabilities and product offerings
  • Focus on innovative therapies positions the company for long-term success
Financial Highlights
  • Q1 2026 revenue of 96.82 billion DKK, a significant increase from previous quarters
  • Net income for Q1 2026 reached 48.56 billion DKK, reflecting strong profitability
  • TTM net profit margin stands at 37.20%, indicating efficient operations
Novo Nordisk A/S has established itself as a key player in the pharmaceutical industry, particularly in diabetes and obesity care. The company's commitment to innovation and strategic partnerships enhances its ability to deliver effective treatments. Recent financial performance demonstrates robust revenue growth and strong profitability, making it an attractive option for potential investors. The focus on research and development, along with a solid product pipeline, positions Novo Nordisk for continued success in the evolving healthcare landscape.
AI Generated • Jul 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

68,794

CEO

Maziar Mike Doustdar

Website

www.novonordisk.com

Headquarters

Bagsvaerd, CR 2880, DK

NONOF Financials

Key Financial Metrics (TTM)

Gross Margin

81.85%

Operating Margin

45.30%

Net Income Margin

37.20%

Return on Equity

66.36%

Return on Capital

40.64%

Return on Assets

21.81%

Earnings Yield

8.40%

Dividend Yield

3.56%

Payout Ratio

42.47%

Stock Overview

Market Cap

$224.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.43B

Volume

207.17K

Avg. Volume

22.20K

Financials (TTM)

Gross Profit

DKK 268.30B

Operating Income

DKK 148.49B

EBITDA

DKK 183.86B

Operating Cash Flow

DKK 118.58B

Capital Expenditure

-DKK 60.33B

Free Cash Flow

DKK 58.25B

Cash & ST Invst.

DKK 21.63B

Total Debt

DKK 146.38B

Novo Nordisk A/s Performance Analysis

Novo Nordisk A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 24,998,461,07711.7%
20232023-12-31DKK 33,700,297,29934.8%
20242024-12-31DKK 42,115,001,36325.0%
20252025-12-31DKK 46,735,785,02911.0%
Novo Nordisk A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.6%
Q32025-09-30-2.4%
Q42025-12-315.3%
Q12026-03-3122.6%
Novo Nordisk A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK 1.734.7%
20232023-12-31DKK 2.7056.5%
20242024-12-31DKK 3.2821.5%
20252025-12-31DKK 3.486.1%
Novo Nordisk A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-8.7%
Q32025-09-30-24.5%
Q42025-12-3134.0%
Q12026-03-3180.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

DKK 96.82B

+24.0%

Gross Profit

DKK 83.23B

+27.7%

Gross Margin

85.96%

N/A

Market Cap

$224.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.91M

N/A

Employees

77,406

N/A

Net Income

DKK 48.56B

+67.2%

EBITDA

DKK 69.21B

+50.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

DKK 21.63B

-48.0%

Total Debt

DKK 146.38B

+23.3%

Accounts Receivable

DKK 100.27B

+44.4%

Inventory

DKK 51.35B

+19.8%

Long Term Debt

DKK 119.17B

+23.7%

Short Term Debt

DKK 27.21B

+21.4%

Return on Assets

21.81%

N/A

Return on Invested Capital

44.45%

N/A

Free Cash Flow

DKK 12.05B

+20.4%

Operating Cash Flow

DKK 24.08B

-2.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RHHVFRoche Holding AG
$405.00-0.99%
NVSEFNovartis AG
$151.90+0.00%
RHHBYRoche Holding AG
$51.60+0.29%
FSNUYFresenius SE & Co. KGaA
$11.99-0.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
TAT&T
$21.81-0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.53-0.05%
SKHYSK Hynix
$154.03+0.01%

Questions About NONOF

What is the current price of Novo Nordisk A/s?

Novo Nordisk A/s is trading at $50.74 per share.

What is the 52-week range for Novo Nordisk A/s?

Over the past 52 weeks, Novo Nordisk A/s has traded between $34.00 and $72.61.

How much debt does Novo Nordisk A/s have?

As of the most recent reporting period, Novo Nordisk A/s reported total debt of DKK 22.57B.

How much cash does Novo Nordisk A/s have on hand?

Novo Nordisk A/s reported DKK 3.26B in cash and cash equivalents in its most recent financial results.

What is Novo Nordisk A/s’s dividend yield?

Novo Nordisk A/s currently has a dividend yield of 3.56%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services